Clinical Trials Browser

Phase 2 × Glioma × Nivolumab × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT03718767 2025-11-24

Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype

Phase 2 Active not recruiting

62 enrolled 17 charts

Glioblastoma, Glioma

NCT03557359 2025-11-03

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Phase 2 Completed

35 enrolled 9 charts

Glioma, Recurrence

NCT04056910 2025-02-27

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Phase 2 Completed

15 enrolled 14 charts

Glioma

NCT03925246 2024-04-02

REVOLUMAB

Phase 2 Completed

Brain Neoplasms, Glioma